Page 2 - ESGO - Vulvar cancer - Complete report_fxd2
P. 2
TABLE OF CONTENTS
1 Introduction................................................................................................................................................................ 4
2 Acknowledgements .................................................................................................................................................... 4
3 Method........................................................................................................................................................................ 4
3.1 Nomination of multidisciplinary international development group ............................................................................ 4
3.2 Identification of scientific evidence ............................................................................................................................ 5
3.3 Formulation of guidelines........................................................................................................................................... 5
3.4 External evaluation of the guidelines - International review....................................................................................... 6
3.5 Integration of international reviewers comments ........................................................................................................ 6
4 Management of conflicts of interest.......................................................................................................................... 6
5 Summary of guidelines .............................................................................................................................................. 7
5.1 Diagnosis and referral ................................................................................................................................................. 7
5.2 Staging system ............................................................................................................................................................ 7
5.3 Preoperative investigations ......................................................................................................................................... 7
5.4 Surgical management.................................................................................................................................................. 8
5.5 Sentinel lymph node procedure................................................................................................................................... 9
5.6 Radiation therapy........................................................................................................................................................ 9
5.7 Chemoradiation......................................................................................................................................................... 10
5.8 Systemic treatment.................................................................................................................................................... 10
5.9 Treatment of recurrent disease.................................................................................................................................. 10
5.10 Follow-up ................................................................................................................................................................. 11
6 Diagnosis and referral ............................................................................................................................................. 12
6.1 Summary of available scientific evidence................................................................................................................. 12
6.2 Previous initiatives.................................................................................................................................................... 12
6.3 Development group comments ................................................................................................................................. 12
6.4 Guidelines................................................................................................................................................................. 12
7 Staging system.......................................................................................................................................................... 13
7.1 Summary of available scientific evidence................................................................................................................. 13
7.2 Previous initiatives.................................................................................................................................................... 13
7.3 Development group comments ................................................................................................................................. 13
7.4 Guidelines................................................................................................................................................................. 13
8 Preoperative investigations ..................................................................................................................................... 15
8.1 Summary of available scientific evidence................................................................................................................. 15
8.2 Previous initiatives.................................................................................................................................................... 16
8.3 Development group comments ................................................................................................................................. 16
8.4 Guidelines................................................................................................................................................................. 17
9 Surgical management .............................................................................................................................................. 20
9.1 Summary of available scientific evidence................................................................................................................. 20
9.2 Previous initiatives.................................................................................................................................................... 24
9.3 Development group comments ................................................................................................................................. 24
9.4 Guidelines................................................................................................................................................................. 25
10 Sentinel lymph node procedure .............................................................................................................................. 26
10.1 Summary of available scientific evidence................................................................................................................. 26
10.2 Previous initiatives.................................................................................................................................................... 29
VULVAR CANCER - GUIDELINES
2